This is a highlights summary of an oral session given at the Virtual EASD Annual Meeting 2021 and presented by:

Dr. Catherine Angwin
University of Exeter
Exeter, UK

Dr. Beverley Shields
University of Exeter
Exeter, UK

The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Prof. Mohamad Hassanein
Dubai Hospital, Gulf Medical University, UAE
Deputy Director of Postgraduate Diabetes Education, Cardiff University, UK
Chair of DAR International Alliance

Prof. Mohamad Hassanein
Dubai Hospital, Gulf Medical University, UAE
Deputy Director of Postgraduate Diabetes Education, Cardiff University, UK
Chair of DAR International Alliance

Dr Hassanein is a senior consultant in Endocrinology and Diabetes at Dubai Hospital, Dubai, UAE since 2014. He holds Academic posts as H Professor of Medicine, Gulf Medical University, UAE, Adjunct Professor of Medicine, Mohamed Bin-Rashid University, UAE, as well as Associate Director for Postgraduate Diabetes Education, Cardiff University, UK since 2007. He was appointed to the post of Consultant in the Department of Endocrinology and Diabetes at BCUHB, UK, in 2002. Dr Hassanein graduated from the Faculty of Medicine, Alexandria, Egypt.

His main research interest is in the field of diabetes and Ramadan. He co-authored recommendations papers on this subject for the American Diabetes Association (ADA) in 2005 and 2010, and for the British Medical Journal in 2010, Diabetes Canada in 2017 as well as the IDF-DAR practical guidelines, 2016 and 2021. Dr Hassanein has participated as the first author and/or a co-author in numerous studies. He has published over 85 papers. He’s also the associate editor of DRCP as well as Dubai Diabetes and Endocrinology Journal.

1. Angwin C, Jenkinson C, Jones A, et al. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol. BMJ Open. 2020;10(12):e042784.